Broad, bold collaborations are the essence of IHI. We build collaborations that bring together Europe's scientific excellence with the research, engineering and product development capabilities of Europe's pharmaceutical and medical device industries to take on large, ambitious projects that no single organisation can tackle alone.
The call 11 topic on precision medicine for brain dysfunction is a great example. Imagine if depression, Alzheimer’s disease or obesity could be assessed with the precise diagnostic tools that have transformed oncology over the last 25 years. If treatments could be developed to directly address the underlying causes of the disease, rather than the symptoms that people are experiencing. This is a difficult field, and true to the spirit of IHI, we are looking for bold, ambitious, cross-sectorial collaborations.
IHI is a unique model for cross-sectorial collaboration, with the ability to mobilise broad coalitions for impactful projects. This is attracting both attention and investments from beyond the EU, and as you can read in this newsletter, in call 11 we are very happy to work with several European and global philanthropic organisations and draw on their strengths and deep engagement in civil society to launch a set of truly transformative projects.
Niklas Blomberg, IHI Executive Director
